fbpx

scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)

BURLINGTON, MA, November 2, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date of June 23, 2018.

about scpharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.

contacts
Investor Relations for scPharmaceuticals, Inc.:
Katherine Taudvin, 781-301-6706
ktaudvin@scpharma.com

Nyheder

Lundbeckfonden øger sit engagement i IO Biotech
12. januar 2021
Lundbeckfonden lancerer 2030-strategi med ambitiøse mål for både uddelings- og erhvervsaktiviteterne
22. december 2020
Lundbeckfonden uddeler 57 mio. kr. til dristige projekter
15. december 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge